What Are Ipamorelin and CJC-1295?
Ipamorelin and CJC-1295 are two synthetic peptides frequently studied together in preclinical research on growth hormone secretagogues (GHS), compounds that influence the signaling systems governing growth hormone release. They belong to different but complementary classes, which is why researchers often investigate them as a pair.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP), a pentapeptide studied for its interaction with the ghrelin receptor. It is noted in the literature for being highly selective, meaning research models tend to show minimal interaction with other signaling systems. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, studied for its ability to model sustained GHRH-pathway signaling.
Together, these peptides represent a common model system for studying how two distinct receptor pathways interact in the regulation of the growth hormone axis. Both are supplied strictly as research chemicals for laboratory use only, not as drugs, supplements, or therapeutic agents. All findings referenced here are preclinical and drawn from experimental models, with no application to human use, dosing, or outcomes.
Recommended Products
Mechanisms and Pathways Researchers Explore
The scientific interest in studying Ipamorelin and CJC-1295 (no DAC) together stems from their action on two separate but converging pathways of the growth hormone axis.
- GHRP pathway (Ipamorelin): Ipamorelin is studied for its selective binding to the growth hormone secretagogue receptor (the ghrelin receptor, GHS-R). Research models examine how this stimulates pulsatile growth hormone signaling. Its selectivity is a key point of interest, as studies note limited interaction with cortisol or prolactin pathways in experimental settings.
- GHRH pathway (CJC-1295): As a GHRH analog, CJC-1295 is studied for how it models the natural growth-hormone-releasing hormone signal. The "no DAC" variant is examined for its shorter-acting profile in research, contrasting with DAC-modified analogs that model prolonged signaling.
- Synergy modeling: Because GHRPs and GHRH analogs act on different receptors, researchers investigate whether combining them in models produces additive or synergistic signaling on the growth hormone axis.
Pre-combined research formats such as CJC-1295 (no DAC) with Ipamorelin exist to support experimental designs studying both pathways simultaneously. Related GHRH-analog compounds like Sermorelin are also studied within this same secretagogue framework, giving researchers a range of tools for characterizing the pathway. These investigations are strictly preclinical and mechanistic in nature.
Research Considerations: Handling, Storage, and Sourcing
Growth hormone secretagogue peptides are sensitive to degradation, making careful handling essential for reliable research. Amino Labs supplies Ipamorelin and CJC-1295 in a lyophilized form, which maximizes stability during shipping and storage. In their freeze-dried state, these peptides should be stored cool, dry, and protected from light until prepared for use.
For laboratory reconstitution, researchers typically use bacteriostatic or sterile water under controlled conditions. Once in solution, these peptides should be kept refrigerated and used within a defined window, as dissolved peptides degrade faster than lyophilized material. Freeze-thaw cycles should be minimized to preserve integrity, which is particularly important when characterizing dose-dependent signaling in secretagogue models.
Because subtle differences in purity can alter experimental results, sourcing matters. Amino Labs tests these peptides to 99%+ HPLC purity, with third-party verification and lyophilized packaging. As a Canadian-owned supplier shipping across Canada via Purolator, Amino Labs provides a traceable, documented supply chain that supports rigorous, reproducible research on the growth hormone axis.